As the coronavirus spreads around the world, it is constantly changing, leading to the emergence of new strains. A variant of the SARS-Cove-2 virus, first discovered in South Africa late last year, is one of the leading health experts on the subject.
South African variant
The South African form, also known as B.3.351, was discovered at the end of the first year. It has since been identified in dozens of countries around the world.
It contains two mutations that have raised concerns that it may be more contagious than previous strains of the virus and may be able to avoid some of the antibody reactions caused by vaccines or previous infections.
The first, known as the N501Y mutation, makes it more likely to bind to human cells, which could increase its transmission. It also contains the E484K conversion, which is thought to help prevent viruses and parts of antibodies.
According to World Health OrganizationPreliminary studies have suggested that the variant was associated with a higher viral load that could suggest an increase in transmissibility, as well as other factors that affect transmissibility are subject to further investigation.
“Moreover, at this stage, there is no clear evidence that the new form is involved in more serious diseases or worse outcomes.”
Do vaccines work against variants?
A real-world study published in Israel on Saturday found that the first form discovered in South Africa could slightly break down the Pfizer-Bioentech coronavirus vaccine.
The study compared about 400 people who tested positive for this cookie after receiving one or two doses of the vaccine for 19, 14 days or more, compared to the same number of undiagnosed patients. Among other features it ched in with age and gender
A study by Tel Aviv University and Clit, Israel’s largest healthcare provider, found that COVID-19 cases accounted for about one percent of all people studying all of South Africa’s alternatives.
However, among patients who received two doses of the vaccine, the prevalence rate of variants was eight times higher than unprotected – from 5.7 percent to 0.7 percent.
It suggests that the vaccine is less effective against the South African variant, compared to the first known carnivirus in the UK and almost all cases of CVID-19 in Israel, which is less effective.
“We have a relatively high rate of South African variant among people receiving the second dose of the vaccine compared to the isolated group. This means that the South African form has been able to break the vaccine’s security, albeit to some extent, “said Adi Stern of Tel Aviv University.
The researchers warned that due to the rarity of Israel, the study included only a small number of people infected with the South African variant.
They added that the study was not intended to reduce the overall effectiveness of the vaccine against any form, as it only aimed at people who had already tested positive for COVID-19, not the overall infection rate.
Pfizer did not immediately comment on the Israeli study, which was not reviewed.
Earlier this month, Pfizer and Bioentech said clinical trial data indicated their CVID-19 vaccine could provide protection against B1.351. In a trial of about 800 participants from a relatively small number of South Africans, the companies found that the shot was 100 percent effective in preventing illness.
Some previous studies have indicated that the Pfizer-Bioentech shot was less effective against the B.1.351 variant than other forms of the coronavirus, but they nevertheless offered a strong defense.
As for the modern vaccine, the manufacturer said in late January that its vaccine was effective against South African strains.
Despite a six-fold reduction in neutralization of antibodies produced against the South African variant, the levels are still higher than those expected to be protective, Modarna said.
Meanwhile, the Oxford-Astrageneca vaccine provides less than 10 percent protection against the variant, the researchers suggested.
A trial of the Johnson & Johnson vaccine, developed in partnership with Johnson Pharmaceuticals, found that it was about 85 percent effective in protecting against severe cases of Covid-19 and 57 percent effective against all types of the disease.